August 21, 2018 | FAH Policy Blog Team
Category: FAH News, Legislation, Pharmaceuticals
Rising and excessive drug prices threaten patient access to the drugs they need and can undermine the care physicians see as necessary for patients. The Grassley-Durbin amendment (#3787) would take a great leap forward in providing consumers useful information on drug prices that could help them buy smart. And, the public display of prices could put a spotlight on those high prices and bring them down.
We agree with the Campaign for Sustainable Rx Pricing’s letter that requiring disclosure of drug pricing in DTC advertising would “provide useful information for consumers as they engage in discussions with their providers about the best treatment options…” The FAH urges the Senate to approve this amendment.
- New Report Shows Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals
- FAH Leader Expresses Opposition to Ruling that Overturns 340B Medicare Regulation
- FAH, AHA Send Joint Letter to Congress on Surprise Billing
- FAH Comments on Proposed Rule Expanding Use of HRAs